April 5th, 2022

TD2 to Highlight Preclinical Progress of Two Novel HDAC Inhibitors at AACR Annual Meeting

SCOTTSDALE, ARIZONA, UNITED STATES, April 5, 2022 / — Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of the preclinical results of two novel, targeted epigenetic inhibitors at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA., to be held April 8-13, 2022. Two posters […]

Read more +

March 30th, 2022

Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302

CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has appointed the renowned contract research organization (CRO) Translational Drug Development (TD2) to lead the […]

Read more +

October 14th, 2021

TD2 Partners with Medidata to Enhance its Clinical Operations and Accelerate Clinical Trials

Medidata, a Dassault Systèmes company, today announced that Translational Drug Development (TD2), a precision oncology contract research organization (CRO), has signed an agreement to adopt Medidata’s Rave CTMS (Clinical Trial Management System) and eTMF (electronic Trial Master File) solutions. Rave CTMS and eTMF are key offerings within Medidata’s Unified Platform, a cutting-edge platform that is transforming the clinical trial experience […]

Read more +

September 16th, 2021

TD2 and Deep Lens Partner to Enable Diversity, Access and Faster Clinical Trial Enrollment for Community Oncology Practices

Key Partnership Will Connect Patients with Precision Oncology Clinical Trials and Novel Therapies, Accelerating Access to Promising Treatments Translational Drug Development (TD2), a leading precision oncology contract research organization (CRO), and Deep Lens have announced a strategic partnership that will enhance access to tailored oncology treatments and novel clinical studies for patients receiving care in […]

Read more +

November 24th, 2020

Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO)

The Companies Plan to Focus On Voltron’s VaxCelerate Vaccine Platform’s Effectiveness and Utility in a Variety of Tumor Settings Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced a strategic development agreement with Translational Drug Development (TD2), a precision oncology contract research organization (CRO). Over time the two companies […]

Read more +


May 21, 2022

Oncology Site Solutions Summit

Austin, Tx | Booth #26

Learn more +

June 3, 2022


Chicago, IL | Booth #2126

Learn more +

September 19, 2022

CAR-TCR Summit

Boston, MA

Learn more +


Get free tips, tools and resources by subscribing to the TD2 newsletter.